Lupin's Nagpur facility receives EIR from US FDA

Pratik Shastri
/ Categories: Trending, Markets

Lupin today announced the receipt of the Establishment Inspection report (EIR) post the completion of a pre-approval inspection for its phenytoin sodium extended release 100 mg capsules, carried out by the US FDA at its Nagpur facility in Maharashtra. The inspection was conducted in September 2018 and concluded without any observations. 
  
Lupin's Nagpur facility is the company's  latest site and manufactures oral solid dosage products  along with  injectable manufacturing facility.  The management has stated  that it is a positive development for the company which shows its ability to meet global standards. 
  
Lupin is a   pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products and APIs globally . It has market cap of Rs. 38661 crore. 
  

The stock reacted in a positive way to this development, recording an intra-day high of Rs 876. At 3.00 p.m. it traded at Rs. 860.90 showing uptick of 0.78 per cent on the BSE. While the BSE Sensex traded at 34885 down by 273 points. 

Previous Article Ten stocks close to their 52-week low
Next Article CIPLA receives approval from US FDA
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList